Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-SEZ6 antibody-drug conjugate ABBV-706

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to an undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration of anti-SEZ6 ADC ABBV-706, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills SEZ6-expressing tumor cells through an as of yet undisclosed mechanism. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, may play a role in cell-cell recognition and in neuronal membrane signaling.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-SEZ6 ADC ABBV-706
Code name:ABBV 706
ABBV-706
ABBV706
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search